These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 11113727)

  • 1. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
    Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
    Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
    Szymanski KM; Wei JT; Dunn RL; Sanda MG
    Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
    Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
    Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.
    Anota A; Mariet AS; Maingon P; Joly F; Bosset JF; Guizard AV; Bittard H; Velten M; Mercier M
    Health Qual Life Outcomes; 2016 Dec; 14(1):168. PubMed ID: 27923377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.
    Ratti MM; Gandaglia G; Alleva E; Leardini L; Sisca ES; Derevianko A; Furnari F; Mazzoleni Ferracini S; Beyer K; Moss C; Pellegrino F; Sorce G; Barletta F; Scuderi S; Omar MI; MacLennan S; Williamson PR; Zong J; MacLennan SJ; Mottet N; Cornford P; Aiyegbusi OL; Van Hemelrijck M; N'Dow J; Briganti A;
    Eur Urol Oncol; 2022 Apr; 5(2):153-163. PubMed ID: 34785188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument.
    Rodrigues G; Bauman G; Venkatesan V; Ahmad B; Lock M; Sexton T; D'Souza D; Stitt L; Eid S
    Can J Urol; 2011 Aug; 18(4):5802-10. PubMed ID: 21854712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
    Umbehr MH; Bachmann LM; Poyet C; Hammerer P; Steurer J; Puhan MA; Frei A
    Health Qual Life Outcomes; 2018 Feb; 16(1):36. PubMed ID: 29458434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment.
    Chung KJ; Kim JJ; Lim SH; Kim TH; Han DH; Lee SW
    Korean J Urol; 2010 Sep; 51(9):601-12. PubMed ID: 20856644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.
    Litwin MS; Hays RD; Fink A; Ganz PA; Leake B; Brook RH
    Med Care; 1998 Jul; 36(7):1002-12. PubMed ID: 9674618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26).
    Fosså SD; Storås AH; Steinsvik EA; Myklebust TA; Eri LM; Loge JH; Dahl AA
    Scand J Urol; 2016 Aug; 50(4):280-5. PubMed ID: 27049891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution.
    Lourenço DB; Amaral BS; Alfer-Junior W; Vasconcellos A; Russo F; Sanchez-Salas R; Bianco B; Wagner AA; Chang P; Moschovas MC; Lemos GC; Carneiro A
    BMC Urol; 2020 Oct; 20(1):163. PubMed ID: 33081748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.
    Marzorati C; Monzani D; Mazzocco K; Masiero M; Pavan F; Monturano M; Pravettoni G
    Health Qual Life Outcomes; 2019 Aug; 17(1):147. PubMed ID: 31464649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.
    Einstein DJ; Patil D; Chipman J; Regan MM; Davis K; Crociani CM; Wagner AA; Sanda MG; Chang P
    Urology; 2019 May; 127():53-60. PubMed ID: 30790648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
    Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
    J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Prostate Cancer Index Composite versus Incontinence Symptom Index and Sexual Health Inventory for Men to measure functional outcomes after prostatectomy.
    Hedgepeth RC; Labo J; Zhang L; Wood DP
    J Urol; 2009 Jul; 182(1):221-7; discussion 227-8. PubMed ID: 19450842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quality of life in patients with prostate cancer: validation of an instrument for clinical practice].
    Balbontín F; Marchetti P; Moreno S; Cabello JM; Urzúa C; Silva A; Avilés J; Badínez L; García J; Salgado A; Vinez E; Alliende I; Canals A; Velasco A
    Arch Esp Urol; 2015 Jun; 68(5):466-73. PubMed ID: 26102050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life using SF-8 and EPIC questionnaires after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy.
    Hashine K; Kusuhara Y; Miura N; Shirato A; Sumiyoshi Y; Kataoka M
    Jpn J Clin Oncol; 2009 Aug; 39(8):502-8. PubMed ID: 19477898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
    Namiki S; Takegami M; Kakehi Y; Suzukamo Y; Fukuhara S; Arai Y
    J Urol; 2007 Aug; 178(2):473-7; discussion 477. PubMed ID: 17561164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation.
    Laviana AA; Zhao Z; Huang LC; Koyama T; Conwill R; Hoffman K; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
    Eur Urol; 2020 Aug; 78(2):248-255. PubMed ID: 32098731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.